Recombinant Human MAdCAM-1 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty

Save Up to 40% on RUO Reagents with BIOSPRING24 (See Details)

Best Seller
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (15)
Supplemental Products
Reviews (3)

Recombinant Human MAdCAM-1 Fc Chimera Protein, CF Summary

Why choose R&D Systems MAdCAM-1 Protein?

  • Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 90%.
  • Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
  • Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
  • Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.

Product Specifications

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Measured by the ability of the immobilized protein to support the adhesion of HuT 78 human cutaneous T cell lymphoma cells. When 5 x 104 cells/well are added to recombinant human MAdCAM-1/Fc Chimera coated plates (2.5 µg/mL with 100 µL/well), approximately 50%-70% will adhere after 1 hour incubation at 37 °C in the presence of 1 mM MnCl2.
Optimal dilutions should be determined by each laboratory for each application.
Mouse myeloma cell line, NS0-derived human MAdCAM-1 protein
Human MAdCAM-1
Accession # AAY82472
N-terminus C-terminus
Accession #
N-terminal Sequence
Val23 & Glu29
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
59.3 kDa (monomer)
85-100 kDa, reducing conditions

Product Datasheets

You must select a language.



Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.


Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 200 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Background: MAdCAM-1

Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is an approximately 60 kDa type 1 transmembrane glycoprotein. It is an endothelial cell adhesion molecule that belongs to the immunoglobulin (Ig) superfamily of proteins (1). Human MAdCAM-1 is synthesized as a 382 amino acid (aa) precursor that contains an 18 aa signal sequence, a 299 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 44 aa cytoplasmic tail. Within the ECD there is one potential site for N-linked glycosylation (2). The ECD comprises two Ig-like domains of 90 aa and 119 aa, respectively, each possessing invariant cysteine residues that stabilize the Ig loop (2). There is also a Ser-Thr-Pro-rich (71%) mucin-like 48 aa domain that is (aa 206 ‑ 317) formed by six tandem repeats of an eight aa sequence having the general consensus DTTSPEP/SP. This mucin domain contains 19 potential sites for O-linked glycosylation (2, 3). A splicing variant in which a single Ala residue is substituted for aa 223 ‑ 334 in isoform 1 produces a second isoform. Human mature MAdCAM-1 shares only 44% aa sequence identity with mature mouse MAdCAM-1. The integrin alpha (4)  beta (7), which is expressed on lymphocytes, functions as the MAdCAM-1 receptor (1). The Ig domains of MAdCAM-1 are critical to alpha (4)  beta (7)  binding, and the mucin domain has activity in L‑Selectin binding. MAdCAM-1 expression is up-regulated by TNF-alpha  and IL‑1 beta. MAdCAM-1 is expressed on the surface of high endothelial venules (HEV) in the gut and in Peyer’s patches, on endothelial cells of the mesenteric lymph nodes, lamina propria of the small and large intestine, and the mammary gland during lactation, and on brain endothelial cells (1). MAdCAM‑1 has also been reported to be expressed in the liver portal region in autoimmune hepatitis (1), and in bone marrow following allogenic (genetically non-identical) hematopoietic stem cell transplantation, where it recruits donor T cells, which may lead to graft versus host disease (3, 4). MAdCAM‑1 functions as a homing receptor, and plays a central role in leukocyte migration into HEVs and Peyer’s patch (5). In addition to its normal role in lymphocyte trafficking to mucosal tissue, MAdCAM‑1 expression is also dramatically increased in chronic inflammatory and disease states (1, 6), including inflammatory bowel disease (Crohn’s disease and ulcerative colitis) (7), sclerosing cholangitis (8), and diabetes (9), and may play an important role in these conditions.

  1. Ando, T. et al. (2007) BMC Physiol. 7:10.
  2. Dando, J. et al. (2002) Acta Crystallogr. D 58:233.
  3. Leung, E. et al. (1996) Immunol. Cell Biol. 74:490.
  4. Ambruzova, Z. et al. (2009) Hum. Immunol. 70:457.
  5. Tada, T. et al. (2008) Exp. Anim. 57:247.
  6. Volpes, R. et al. (1992) Hepatology 15:269.
  7. Connor, E.M. et al. (1999) J. Leukoc. Biol. 65:349.
  8. Ala, A. et al. (2001) Gut 49:3043.
  9. Yang, X.D. et al. (1997) Diabetes 46:1542.
Long Name
Mucosal Addressin Cell Adhesion Molecule 1
Entrez Gene IDs
8174 (Human); 17123 (Mouse)
Alternate Names
hMAdCAM-1; MACAM1; MAdCAM1; MAdCAM-1; mucosal addressin cell adhesion molecule 1; mucosal addressin cell adhesion molecule-1; mucosal vascular addressin cell adhesion molecule 1

Citations for Recombinant Human MAdCAM-1 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

15 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. The Force-Dependent Mechanism of an Integrin ?4?7-MAdCAM-1 Interaction
    Authors: Su, Y;Luo, Z;Sun, D;Yang, B;Li, Q;
    International journal of molecular sciences
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. E-selectin-mediated rapid NLRP3 inflammasome activation regulates S100A8/S100A9 release from neutrophils via transient gasdermin D pore formation
    Authors: Pruenster, M;Immler, R;Roth, J;Kuchler, T;Bromberger, T;Napoli, M;Nussbaumer, K;Rohwedder, I;Wackerbarth, LM;Piantoni, C;Hennis, K;Fink, D;Kallabis, S;Schroll, T;Masgrau-Alsina, S;Budke, A;Liu, W;Vestweber, D;Wahl-Schott, C;Roth, J;Meissner, F;Moser, M;Vogl, T;Hornung, V;Broz, P;Sperandio, M;
    Nature immunology
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Force-Regulated Calcium Signaling of Lymphoid Cell RPMI 8226 Mediated by Integrin ?4?7/MAdCAM-1 in Flow
    Authors: Sun, D;Luo, Z;Kong, Y;Huang, R;Li, Q;
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Irisin supports integrin-mediated cell adhesion of lymphocytes
    Authors: PK Myint, A Ito, MG Appiah, G Obeng, S Darkwah, E Kawamoto, A Gaowa, EJ Park, M Shimaoka
    Biochemistry and Biophysics Reports, 2021-03-08;26(0):100977.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay, ELISA Capture Control
  5. Circulating exosomes express &alpha4&beta7 integrin and compete with CD4+ T cells for the binding to Vedolizumab
    Authors: R Domenis, M Marino, A Cifù, G Scardino, F Curcio, M Fabris
    PLoS ONE, 2020-11-12;15(11):e0242342.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
    Authors: C Allner, M Melde, E Becker, F Fuchs, L Mühl, E Klenske, L Müller, N Morgenster, K Fietkau, S Hirschmann, R Atreya, I Atreya, MF Neurath, S Zundler
    BMC Gastroenterol, 2020-04-15;20(1):103.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model
    Authors: A Natoni, ML Farrell, S Harris, C Falank, L Kirkham-Mc, MS Macauley, MR Reagan, M O' Dwyer
    Haematologica, 2020-01-31;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
    Authors: C Lichnog, S Klabunde, E Becker, F Fuh, P Tripal, R Atreya, E Klenske, R Erickson, H Chiu, C Reed, S Chung, C Neufert, I Atreya, J McBride, MF Neurath, S Zundler
    Front Pharmacol, 2019-02-01;10(0):39.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to ?4?7
    Authors: S Lertjuthap, C Cicala, D Van Ryk, M Liu, J Yolitz, D Wei, F Nawaz, A Doyle, B Horowitch, C Park, S Lu, Y Lou, S Wang, R Pan, X Jiang, F Villinger, SN Byrareddy, PJ Santangelo, L Morris, CK Wibmer, K Biris, RD Mason, J Gorman, J Hiatt, E Martinelli, M Roederer, D Fujikawa, G Gorini, G Franchini, A Arakelyan, AA Ansari, K Pattanapan, XP Kong, AS Fauci, J Arthos
    PLoS Pathog., 2018-08-28;14(8):e1007278.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay, Surface Plasmon Resonance
  10. ??CD4effector/effector memory T cells differentiate into productively and latently infected central memory T cells by TGF?1 during HIV-1 infection
    Authors: KW Cheung, T Wu, SF Ho, YC Wong, L Liu, H Wang, Z Chen
    J. Virol., 2018-03-28;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. RAR?/RXR Synergism Potentiates Retinoid Responsiveness in Cutaneous T Cell Lymphoma Cell Lines
    Authors: L Wang, SS DeMarco, MS Peaks, AL Maiorana-B, J Chen, MJ Crouch, BM Shewchuk, SR Shaikh, CM Phillips, LC Bridges
    Exp. Dermatol., 2017-07-03;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to alpha4beta7 Integrin Receptor.
    Authors: Peachman K, Karasavvas N, Chenine A, McLinden R, Rerks-Ngarm S, Jaranit K, Nitayaphan S, Pitisuttithum P, Tovanabutra S, Zolla-Pazner S, Michael N, Kim J, Alving C, Rao M
    PLoS ONE, 2015-12-01;10(12):e0143895.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Envelope glycoprotein binding to the integrin alpha4beta7 is not a general property of most HIV-1 strains.
    Authors: Perez L, Chen H, Liao H, Montefiori D
    J Virol, 2014-07-09;88(18):10767-77.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. The alpha4beta7 integrin binds HIV envelope but does not mediate bystander killing of gamma/delta T cells.
    Authors: Li H, Pauza CD
    Blood, 2012-07-19;120(3):698-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. HIV envelope-mediated, CCR5/alpha4beta7-dependent killing of CD4-negative gammadelta T cells which are lost during progression to AIDS.
    Authors: Li H, Pauza CD
    Blood, 2011-09-16;118(22):5824-31.
    Species: Human
    Sample Types: Whole Cells
    Applications: Binding Assay


No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human MAdCAM-1 Fc Chimera Protein, CF

Average Rating: 5 (Based on 3 Reviews)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Recombinant Human MAdCAM-1 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Recombinant Human MAdCAM-1 Fc Chimera Protein, CF
By tenny tang on 12/07/2018
Application: Cell Adhesion

Recombinant Human MAdCAM-1 Fc Chimera Protein, CF
By tenny tang on 10/18/2018
Application: CellProlif

Recombinant Human MAdCAM-1 Fc Chimera Protein, CF
By tenny tang on 05/31/2018
Application: Cell Adhesion
Reason for Rating: this protein worked out well in my adhesion assay. Following the instruction provided, I successfully validated the inhibitory function of my compounds.